Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Tuberous sclerosis medical therapy

Introduction

Overview

Overview

Medical therapy is generally preferred over surgical ones due to their fewer number of complications and diminishing side effects over time.

Medical Therapy

Medical Therapy

Epilepsy

  • Anti-seizure medications can be prescribed to control seizures. The preferred medication is vigabatrin[1], but other anticonvulsants, clobazam, ketogenic diet, or surgical procedures.[2] Treatment before the onset of epilepsy and other neuropsychiatric manifestations may be beneficial, but trials testing this approach are still ongoing (EPISTOP trial). mTOR inhibitors may present with some anti-epileptogenic properties.[2]

Lymphangioleiomyomatosis

Angiomyolipoma

  • Treatment is done in a pre-emptive manner to prevent bleeding, reduce tumor size or slow its growth. Systemic everolimus is the preferred method nowadays but there are also surgical options. [2]

Subependymal Giant Cell Astrocytoma

  • Treatment with mTOR inhibitors have been recommended, being well tolerated and presenting with side effects that decreases over time.[2] There are also surgical procedures but they have important complications.

Tuberous Sclerosis Complex-associated Neuropsychiatric Disorder

  • There are no specific interventions, patients must be followed closely by a psychiatrist. Trials exploring the use of mTOR inhibitors for this manifestation are ongoing.[2]

Skin Lesions

For TSC-associated skin lesions, the following treatments may be performed:

  • Sun protection;
  • “Camouflage make-up”
  • Topical mTOR inhibitors.
  • There are surgical options and ablation.

mTOR Inhibitors side effect:

mTOR inhibition therapy may cause stomatitis, diabetes, hyperlipidemia, wound-healing complications, infertility and delayed sexual maturation.[2]

References

References

  1. ↑ Tsao CY (2009). “Current trends in the treatment of infantile spasms”. Neuropsychiatr Dis Treat. 5: 289–99. PMC 2695218. PMID 19557123.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Henske, Elizabeth P., et al. “Tuberous sclerosis complex.” Nature reviews Disease primers 2.1 (2016): 1-18.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]